Somewhat Positive Press Coverage Somewhat Unlikely to Impact Omnicell (OMCL) Stock Price

News headlines about Omnicell (NASDAQ:OMCL) have been trending somewhat positive on Sunday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Omnicell earned a news impact score of 0.14 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.2548816462358 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

OMCL has been the topic of a number of recent analyst reports. Oppenheimer reiterated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research report on Thursday, October 19th. Cantor Fitzgerald reiterated a “buy” rating and issued a $60.00 target price on shares of Omnicell in a research report on Wednesday, December 13th. Craig Hallum reiterated a “buy” rating and issued a $62.00 target price (up previously from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Zacks Investment Research upgraded Omnicell from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Finally, BidaskClub cut Omnicell from a “hold” rating to a “sell” rating in a research report on Friday, December 22nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $55.14.

Omnicell (NASDAQ:OMCL) opened at $50.75 on Friday. Omnicell has a 12-month low of $32.35 and a 12-month high of $55.40. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08. The stock has a market capitalization of $1,913.69, a PE ratio of -461.36, a price-to-earnings-growth ratio of 4.00 and a beta of 0.71.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, October 26th. The company reported $0.42 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.42. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The firm had revenue of $186.78 million for the quarter, compared to analyst estimates of $192.45 million. During the same period last year, the firm posted $0.40 earnings per share. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. equities research analysts forecast that Omnicell will post 0.12 EPS for the current year.

In other news, EVP Dan S. Johnston sold 14,613 shares of Omnicell stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $47.81, for a total transaction of $698,647.53. Following the sale, the executive vice president now directly owns 43,621 shares of the company’s stock, valued at $2,085,520.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Peter J. Kuipers sold 1,926 shares of Omnicell stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $51.69, for a total value of $99,554.94. Following the sale, the chief financial officer now directly owns 40,544 shares in the company, valued at $2,095,719.36. The disclosure for this sale can be found here. Insiders have sold 27,558 shares of company stock worth $1,330,230 over the last three months. Insiders own 3.77% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Omnicell (OMCL) Stock Price” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/01/14/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-omnicell-omcl-stock-price-2.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply